A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Mismatched Unrelated Allogeneic Stem Cell Transplantation

Trial Profile

A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Mismatched Unrelated Allogeneic Stem Cell Transplantation

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Methotrexate; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Mar 2017 Planned End Date changed from 1 Jan 2017 to 31 Jan 2020.
    • 19 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Jan 2017.
    • 07 Jan 2016 Planned End Date changed from 1 Apr 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top